Benjamin G. Neel, MD, PhD, became director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, an NCI-designated cancer center in New York, NY, in January. He succeeds William L. Carroll, MD.
A renowned cancer biologist and expert in cell signal transduction, Neel previously served as director of the Ontario Cancer Institute at Princess Margaret Cancer Center, Canada's largest cancer research center, a position he held for 14 years. He was also a professor of medical biophysics at the University of Toronto. His research focuses on cell signaling in cancer and developmental disease, the functional genomics of breast cancer, and ovarian cancer tumor–initiating cells.
In his new role, Neel will oversee the building of world-class translational programs in immunotherapy; cancer genetics, targeted therapies and epigenetics; imaging; community outreach; and supportive care.
Bristol-Myers Squibb announced that Giovanni Caforio, MD, the company's current chief operating officer, will become its CEO effective May 5. He will succeed Lamberto Andreotti, who will become executive chairman of the board, a position he will retain after he retires in August.
After earning his medical degree at the University of Rome in Italy, Caforio began his career in medical affairs at Abbott Laboratories, where he spent 12 years in various leadership positions. He joined Bristol-Myers Squibb in 2000 as vice president and general manager, Italy, in the Worldwide Medicines Group. In 2007, he was named senior vice president, U.S. Oncology. In 2010, he was named senior vice president, Global Commercialization, Oncology and Immunology, before becoming president of U.S. operations in 2011.
For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.
